Clinical Trials

2,431 enrolled 13 charts

Colonic Neoplasms

NCT02997228 2026-03-18

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled

Colorectal Neoplasms

NCT02890355 2026-03-05

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

123 enrolled 15 charts

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT04166318 2026-03-02

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

252 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT04233866 2026-03-02

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

176 enrolled

Pancreatic Neoplasms

NCT04248452 2026-03-02

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

314 enrolled

Adenocarcinoma Of Esophagus

NCT02912559 2026-02-02

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

712 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT04523818 2026-01-14

Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma

25 enrolled

Clinical Stage I Gastric Cancer AJCC v8

NCT03533582 2025-12-22

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

537 enrolled

Fibrolamellar hepatocellular carcinoma, Hepatoblastoma

NCT05836584 2025-12-01

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

240 enrolled

Phase 1/2 Active not recruiting

Clinical Stage I Gastric Cancer AJCC v8

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

20 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT03776487 2025-11-03

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT04481204 2025-10-09

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

105 enrolled

Borderline Resectable Pancreatic Adenocarcinoma

NCT03073785 2025-05-25

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

46 enrolled

Phase 2/3 Active not recruiting

Pancreatic Neoplasms

NCT04068103 2025-05-07

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

635 enrolled 9 charts

Phase 1 Active not recruiting

Colonic Neoplasms

NCT04535401 2024-10-10

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

10 enrolled

Phase 1/2 Active not recruiting

Stomach Neoplasms, Colorectal Neoplasms

NCT03337087 2024-05-17

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

18 enrolled 12 charts